Replies to post #141414 on Biotech Values

[iwfal]

SNTA -

My sense is they would be seeking upwards of $50m upfront for an Asian partnership. Clearly they haven't been offered that to date since they keep delaying signing a deal

I would suggest, based upon the data everyone has posted on previous deals, that this is unrealistic. $50M or even $100M seems possible, even reasonable, (based upon previous deals) for strong data coming out of randomized ph ii's (assuming both the ALK+ and the chemo subset are strong). But only for WW rights - not just Asia. Do you have an example of high up-front for Asia-only deal?

by that point SNTA could give interested parties data from the ongoing ALK open label trial to see if the 50% RR is holding up

Not clear to me that they will be able to enroll that fast since there is now a highly efficacious drug for that population (ALK+, crizotonib-naive). I'd expect the Criz/G synergy trial to enroll much faster, but it seems to be starting slower (e.g. not yet on Clinicaltrials). That said, obviously the Criz/G trial is more of risk since they have no data for this protocol.

[turtlepower]

SNTA - Upwards of 50M for Asia alone suggests a deal equivalent to what PCYC got. Is the Ganetespib potential equivalent to the potential of pci-765, a best in class monotherapy?

BTW today's SNTA presentation has a 5'th subgroup, LDH. Also the presentation indicates there are two subgroups that the p3 will focus on.